We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immune Responses Evaluated for Tick-Borne Encephalitis

By LabMedica International staff writers
Posted on 13 May 2020
Tick-borne encephalitis (TBE) is an important vector-borne infection of the central nervous system (CNS). The majority of all reported cases of TBE occur in adults. However, TBE should also be included in the differential diagnosis of pediatric CNS infections in endemic areas.

The chemokine CXCL13 is one of the key determinants of the humoral immune response at the site of an infection. CXCL13 is expressed in lymphoid organs and controls the recruitment and compartmentalization of B-cells and CD4+ T lymphocytes within these structures. CXCL13 is produced by microglia, stromal cells in the meninges, and infiltrating lymphoid cells.

Image: The Simultest IMK-Lymphocyte is a two-color direct immunofluorescence reagent kit for enumerating percentages of the following mature human leucocyte subsets in erythrocyte-lysed whole blood (Photo courtesy of BDBiosciences).
Image: The Simultest IMK-Lymphocyte is a two-color direct immunofluorescence reagent kit for enumerating percentages of the following mature human leucocyte subsets in erythrocyte-lysed whole blood (Photo courtesy of BDBiosciences).

Infectious disease specialists at the Medical University of Bialystok (Bialystok, Poland) analyzed anti-tick-borne encephalitis virus (TBEV) antibody levels, cerebrospinal fluid (CSF) and blood lymphoid populations, and concentrations of CXCL13 (a potent B-cell and T-cell chemoattractant), in 35 patients with TBE (20 adults and 15 children). TBE was defined as a febrile illness with signs of meningitis or meningoencephalitis, a CSF cell count of more than 5 cells/μL, and the presence of serum IgM and IgG antibodies to TBEV.

The detection of anti-TBEV IgG and IgM antibodies in serum and CSF was performed by enzyme-linked immunosorbent assay (ELISA), using SERION ELISA classic kits (Würzburg, Germany). The CXCL13 concentration quotient was calculated as QCXCL13 = CXCL13CSF/CXCL13serum. QCXCL13 was used as a measure of the chemical gradient of that chemokine. A value greater than 1 indicates a higher concentration of CXCL13 in the CSF than in the serum. All serum and CSF samples were stored at −80 °C until analysis of the chemokine. For flow cytometry, samples were analyzed within 18 hours on a FACSCanto II cytometer (BDBiosciences, San Jose, CA, USA). The Simultest IMK-Lymphocyte kit from BD Biosciences was used to study peripheral blood and CSF lymphocyte fractions

The scientists reported that when compared with the blood, the CSF lymphoid population was significantly enriched in CD4+ T-cells and relatively depleted in natural killer (NK) cells and B lymphocytes. In comparison with TBE meningitis, patients suffering from TBE meningoencephalitis (11, 31%) had a 3.5-fold higher median CSF CXCL13 concentration, 1.8-fold higher CSF/serum ratio of anti-TBEV IgG antibodies, and 1.8-fold higher median CSF cell count. CSF CXCL13 levels did not change significantly in children with TBE meningitis receiving supportive treatment, but decreased in children with TBE meningoencephalitis who received intravenous steroids.

The authors concluded that the CSF in patients with TBE was abundant in CD4+ cells and relatively depleted in NK cells and in B lymphocytes, when compared with the blood. A higher absolute number of lymphocytes in the CSF were associated with a more severe course of TBE. CXCL13 may be involved in the neuropathology of TBE by attracting different subsets of lymphocytes into the CSF, but it remains unclear whether this chemokine contributes directly to disease severity. The study was published on April 1, 2020 in the International Journal of Infectious Diseases.

Related Links:
Medical University of Bialystok
SERION
BDBiosciences



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Latest Immunology News

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment